Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M1jXVmZ2dmO2aX;uJGF{e2G7 MkjWNE42yqEQvF2= NGD1XlczPCCq M1LvWJdifGW{ NEH2U45ud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? M37DeVI2OTJ|MEiy
Eca109 NWnSOHROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1T5PVAvPS9{LkWvOUDPxE1? NFrIblAzPC92OD:3NkBp NHzTOGd4[XSnch?= MXvpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ MYmyOVEzOzB6Mh?=
Eca109 NEnOS2tHfW6ldHnvckBCe3OjeR?= M2HhbFAvPcLizszN NXXEO2dEPi9zMj:yOEBp NX;MXVdlf2G2ZYK= NF63ZpRqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MWWyOVEzOzB6Mh?=
Eca109 NWfWTlkzTnWwY4Tpc44hSXO|YYm= NWDFRXRjOC53wrFOwG0> NYWx[5ZGOjRiaB?= MkXVe4F1\XJ? M{XhbYlvcGmkaYTzJINmdGxiaX72ZZNqd25? M2fsbVI2OTJ|MEiy
Eca109 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG3NE42yqEQvF2= NX3CcWZzOjRiaB?= NHzDNXN4[XSnch?= M4DSfolv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> MonUNlUyOjNyOEK=
Eca109 MXHGeY5kfGmxbjDBd5NigQ>? MYOwMlUwOSEQvF2= NHLiV2czPCCq MoHCe4F1\XJ? MVvk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz NGrVUW0zPTF{M{C4Ni=>
SW1116  NWrB[|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnzc3ExOC53L{GvNk82KM7:TR?= NYi0Z5g{PDhiaB?= MYnEUXNQ MU\lcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u M4PTUVI1QDd2Mki2
LOVO M3v4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W1XlAvPS9zL{KvOUDPxE1? NFnwNVc1QCCq NXmwcJpGTE2VTx?= M{P5foVvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44> NYf3ToREOjR6N{SyPFY>
SW1116  NVvuU45OTnWwY4Tpc44hSXO|YYm= MXexNEDPxE1? MXi0PEBp Mn\CSG1UVw>? NUn0cIQ2cW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NVnXW5U{OjR6N{SyPFY>
LOVO NVjLWo9UTnWwY4Tpc44hSXO|YYm= MXexNEDPxE1? NFjBOYs1QCCq MkjnSG1UVw>? M4TTeYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MoPDNlQ5PzR{OE[=
SW1116  Mkn6RZBweHSxc3nzJGF{e2G7 MmLWNVAh|ryP MoS5OFghcA>? NEW5OZVFVVOR MVXlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= MX[yOFg4PDJ6Nh?=
LOVO NHPq[GRCeG:ydH;zbZMhSXO|YYm= M13QWVExKM7:TR?= MmGzOFghcA>? NYLBSGV2TE2VTx?= M4LtW4VvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> NUnGSWlsOjR6N{SyPFY>
RPMI-8226 MY\BdI9xfG:|aYOgRZN{[Xl? NVjVVI84OS9{IN88US=> NXPsVodDPDhxN{KvPVYhcA>? NX\1NlNVTE2VTx?= MnTobY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MYKyOFg{OzFyOB?=
OPM-2  M1PDTmFxd3C2b4Ppd{BCe3OjeR?= NXTPTm1lOS9{IN88US=> MmfkO|IwQTZxMUKwJIg> M{fSTWROW09? MUfpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M17zdlI1QDN|MUC4
JJN3  MYDBdI9xfG:|aYOgRZN{[Xl? MlXGNE42NzFizszN MmPjNlQwPDhiaB?= M1;zTWROW09? MXPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUCyOFg{OzFyOB?=
NCI-H929  NVyzWppxSXCxcITvd4l{KEG|c3H5 M3PNbFEwOiEQvF2= MojXO|IwQTZxMUKwJIg> NX36R2JtTE2VTx?= MmSybY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHPjT2QzPDh|M{GwPC=>
RPMI-8226 NHexVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILLV|IyNzJizszN M2PacFI1NzR6L{eyJIg> M3zCcGROW09? NIXEVlZi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NGradlIzPDh|M{GwPC=>
OPM-2  MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\4RVEwOiEQvF2= NF;BXlYzPC92OD:3NkBp NFTvZVFFVVOR MUnh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NFrQTmUzPDh|M{GwPC=>
JJN3  NHnMVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjnUJIxNjVxMTFOwG0> MkHYNlQwPDhxN{KgbC=> MlHQSG1UVw>? MXTh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NWTDO41wOjR6M{OxNFg>
NCI-H929  NXPGO2xyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e2VlEwOiEQvF2= M2XKflI1NzR6L{eyJIg> M4raT2ROW09? MXrh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NVS5XmF1OjR6M{OxNFg>
HeLa MUPLbY5ie2ViQYPzZZk> NVO2[Y1KU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? MX2yOFc5ODB7OB?=
HeLa NVTzbotTU2mwYYPlJGF{e2G7 M1XLT2tqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> MoHpNlQ4QDByOUi=
HeLa NVr6em12U2mwYYPlJGF{e2G7 NFe0[XNMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy MkOxNlQ4QDByOUi=
HeLa MXPLbY5ie2ViQYPzZZk> MnT4T4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NF3MfHQzPDd6MEC5PC=>
NB4 NWPiUnd6TnWwY4Tpc44hSXO|YYm= MljLNk42NzVxNz61M|ExKM7:TR?= MVGyOEBp MmfmSG1UVw>? Ml\BbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MkD4NlQ1QDR6N{C=
CD4+ CD25− T  NFLlTXdHfW6ldHnvckBCe3OjeR?= MW[xM|Uh|ryP MnzWdoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v NWH2So5mOjR2N{[zOlA>
BV-173 M374b2Fxd3C2b4Ppd{BCe3OjeR?= MYCwMlI2NzBwNT:wMlc2NzFizszN M2XkXlQ5Nzd{L{m2JIg> NV3XfVZ{yqCSQmO= MYjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MVKyOFQzOzZzMx?=
ML-1 MWnBdI9xfG:|aYOgRZN{[Xl? NV7lRVZ[OC5{NT:wMlUwOC55NT:xJO69VQ>? M4PaflQ5Nzd{L{m2JIg> NXzPZ3JryqCSQmO= MnnDbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M4TvN|I1PDJ|NkGz
HL-60 NHXjelJCeG:ydH;zbZMhSXO|YYm= MUWwMlI2NzBwNT:wMlc2NzFizszN NXrie2RmPDhxN{KvPVYhcA>? M4ixceKhWEKV M3LEb4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NXvNPXU4OjR2MkO2NVM>
KG-1a NHPrdFRCeG:ydH;zbZMhSXO|YYm= MWiwMlI2NzBwNT:wMlc2NzFizszN MWq0PE84Oi97NjDo NYXvNm92yqCSQmO= MoLhbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M{\2NFI1PDJ|NkGz
BV-173 M2PGZmZ2dmO2aX;uJGF{e2G7 M{jEelI2OC93MEDuUS=> MYi0PEBp M3PMOeKhWEKV MWnpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NGfhenozPDR{M{[xNy=>
CEM M3\y[2Z2dmO2aX;uJGF{e2G7 NHnjZXkzPTBxNUCwcm0> NIHSbpc1QCCq NXrMfJJDyqCSQmO= NUDp[oRFcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NF\aT2gzPDR{M{[xNy=>
HL-60 MkK0SpVv[3Srb36gRZN{[Xl? NF7ISmYzPTBxNUCwcm0> NFH4[FY1QCCq NV\EVHVnyqCSQmO= NYrhWXV{cW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MXWyOFQzOzZzMx?=
ML-1 M4\tdGZ2dmO2aX;uJGF{e2G7 NGH0doczPTBxNUCwcm0> M4\XNFQ5KGh? NVu0O|A6yqCSQmO= NYTESHFzcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NInzbFMzPDR{M{[xNy=>
DLD-1 MkTUSpVv[3Srb36gRZN{[Xl? MYWyOVAwPTBybl2= MmLGOFghcA>? MoPKxsBRSlN? NHfRO3lldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MmKzNlQ1OjN4MUO=
HCT-116 MXvGeY5kfGmxbjDBd5NigQ>? M1zu[VI2OC93MEDuUS=> MYK0PEBp NVfBR2RyyqCSQmO= NV3UeVZK\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MX:yOFQzOzZzMx?=
U937-A/E-9/14/18  M2Hic2Fxd3C2b4Ppd{BCe3OjeR?= NXHGd|lHOC5yMT:wMlEwOS9zMDFOwG0> NWfUSXZoPDhiaB?= NH\vb2hqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWGyOFMxODR3Nh?=
HT29 M1Psemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Dle|czKGh? MVjJR|UxRTF2MEFCtVE4QSEQvF2= NXnJdpI1OjRzN{KwOlE>
SW48 NV:2c4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHSXZdoPzJiaB?= Mn:0TWM2OD1zNT6yxtE3NjJizszN MYWyOFE4OjB4MR?=
HCT116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzxPHQ4OiCq NUj6Rmw5UUN3ME2xMlfDuTBwNDFOwG0> MUeyOFE4OjB4MR?=
HepG2 MUjGeY5kfGmxbjDBd5NigQ>? NXrsXGtCOC53L{Gg{txO MVKyOEBp NUTyXoNGTE2VTx?= MUf1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? MYqyOFE1Pjh5NB?=
LS174T M3jk[WZ2dmO2aX;uJGF{e2G7 NELLRXYxNjVxMTFOwG0> Mn7zNlQhcA>? NXzZUYdDTE2VTx?= M3f1XYxm[WRidH:gZY4hcW6lcnXhd4Uhd2ZiT1PUUlIhdGW4ZXzz M2\pbFI1OTR4OEe0
HepG2 MmLJRZBweHSxc3nzJGF{e2G7 MlK2NU8yOC9zMECg{txO MX[3JIQ> MoDKSG1UVw>? Mn36bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NX7JT4ZGOjRzNE[4O|Q>
LS174T NFLYO3dCeG:ydH;zbZMhSXO|YYm= NXLuVIFrOS9zMD:xNFAh|ryP M2G1NFch\A>? NU\qfIw6TE2VTx?= NUHHdYZRcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1nSblI1OTR4OEe0
QBC-939 NF3uZVRCeG:ydH;zbZMhSXO|YYm= MX2xM|ExNzFyMDFOwG0> Mlj3O{Bl MkPXSG1UVw>? M3vp[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NX\Gd4hVOjRzNE[4O|Q>
U251 NEP1bmlCeG:ydH;zbZMhSXO|YYm= NWP3cYxJOS9zMD:xNFAh|ryP NYfCSlR2PyCm M{fYb2ROW09? M3v4VYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWiyOFE1Pjh5NB?=
HL-60 NVTJV4RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzkellwOSEQvF2= M4frNFQ5KGh? MnjybY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? M3i0TFI1ODByM{K0
MDA‑MB‑453 NWDlUoViTnWwY4Tpc44hSXO|YYm= NF[x[owxNjJxMTFOwG0> M3HaPVczKGh? NVPCVYlx[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NGLyemczOzh2NEKyPC=>
HCC1569 NHfGU|dHfW6ldHnvckBCe3OjeR?= M{\wWVAvOi9zIN88US=> NFraVVk4OiCq M2DkdYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NYDhPXBpOjN6NESyNlg>
BT‑474 MoOzSpVv[3Srb36gRZN{[Xl? MmjnNE4zNzFizszN MV63NkBp MY\jZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= MoW0NlM5PDR{Mki=
AGS NVrRN5JqSXCxcITvd4l{KEG|c3H5 NV;YSXpWPS9zMD:yNE82OCEQvF2= MoPTOFjDqGkEoB?= MUHEUXNQ NU\KVpFlcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? NFrncmEzOzV6Mke4OC=>
A549 NUX5d29OSXCxcITvd4l{KEG|c3H5 M3nOdFUwOTBxMkCvOVAh|ryP MVm0POKhcMLi NID0SXRFVVOR MVPpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> MUeyN|U5Ojd6NB?=
AGS  Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPaZYpJPS9zMD:yNE82OCEQvF2= NXrwN2NZPDkEoHlCpC=> NGfQTIhFVVOR M1\EdIlv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> NXXKSGw1OjN3OEK3PFQ>
Kasumi-1 MV7BdI9xfG:|aYOgRZN{[Xl? MWCwMlUh|ryP M2DKVVQ5yqCqwrC= M4HVd4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj Mm\DNlM1QTN|NEi=
OCI-AML3 M2\6d2Fxd3C2b4Ppd{BCe3OjeR?= M{HySlIvPSEQvF2= NV7GPII{PDkEoHlCpC=> MYjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M1XEc|I{PDl|M{S4
MV4-11 MkDSRZBweHSxc3nzJGF{e2G7 MoHiNk42KM7:TR?= MnX2OFjDqGkEoB?= M{fMNoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj M3PuXVI{PDl|M{S4
NK  NXuxemdOS3m2b4TvfIl1gSCDc4PhfS=> NIfTZ3YxNjB{LUKwJO69VQ>? M3TqbVUh\A>? MnPW[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? Mmj3NlM{OjhyOEi=
NK  M4TVT2Fxd3C2b4Ppd{BCe3OjeR?= M1nLUVAvODJvMkCg{txO M2HyS|Uh\A>? MnLm[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MYSyN|MzQDB6OB?=
NK  NETmWJNHfW6ldHnvckBCe3OjeR?= NY[yToozOC5yMT2yNEDPxE1? M4Hu[|Uh\A>? MVjjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl NFu1VZUzOzN{OEC4PC=>
MOLT4/DNR MmfESpVv[3Srb36gRZN{[Xl? NGrTZpo2KM7:TR?= MWG0JIQ> MXXy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> MYKyN|A3ODV5MB?=
Jurkat/DOX MnrKSpVv[3Srb36gRZN{[Xl? NGnJdHE2KM7:TR?= NGeyO2k1KGR? NWDEcIVNemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MnK2NlMxPjB3N{C=
MOLT4/DNR NGjvdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXRZ5A2KM7:TR?= NVKz[mxlPCCm M2r3S5Jm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MXmyN|A3ODV5MB?=
Jurkat/DOX M{\tWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPkOUDPxE1? M4LCRlQh\A>? MlHhdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NF7YO3EzOzB4MEW3NC=>
ccRCC  MULBdI9xfG:|aYOgRZN{[Xl? NIS2NY4xNjBzLUGw{txO NI\s[ZU4OiCq NGXLZYJFVVOR M3rUb4hieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NVi1NmlMOjJ6Mk[0Olc>
TNBC  MWPBdI9xfG:|aYOgRZN{[Xl? MmfRNE4xOS1zMN88US=> MWG3NkBp M1T2[WROW09? NH7LVodp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MUSyNlgzPjR4Nx?=
A498 NGToeIxCeG:ydH;zbZMhSXO|YYm= NFPwb2IxNjBzLUGw{txO NXuxNXZ3PzJiaB?= NWDzNINKTE2VTx?= MoPqbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NX\MXXQzOjJ6Mk[0Olc>
KIJ265T Mnv4RZBweHSxc3nzJGF{e2G7 M{\ONFAvODFvMUFOwG0> M1rZdlczKGh? MkHVSG1UVw>? MX\pcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MkTmNlI5OjZ2Nke=
MDA-231 MVHBdI9xfG:|aYOgRZN{[Xl? MWSwMlAyNTFyzszN MkmyO|IhcA>? M2L3[WROW09? NITJe2xqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MnfaNlI5OjZ2Nke=
BT-20 MlHyRZBweHSxc3nzJGF{e2G7 MoHkNE4xOS1zMN88US=> NHvOfIw4OiCq M1Xu[mROW09? MlHvbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MVKyNlgzPjR4Nx?=
U937 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe1MVIxKM7:TR?= MmWwNlQwPDhxN{KgbC=> M{OyT4lv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M1;ib|IzPzZ5MEKx
HL60 Mn;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK1MVIxKM7:TR?= M{jUUFI1NzR6L{eyJIg> MYTpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHvidGkzOjd4N{CyNS=>
U937 NYj6XI0{SXCxcITvd4l{KEG|c3H5 NGTzOnoyPSEQvF2= MoixNlQwPDhxN{KgbC=> NGfhcWhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NIS5[IczOjd4N{CyNS=>
HL60 MoLIRZBweHSxc3nzJGF{e2G7 NXnWdJdsOTVizszN NWLoS3FzOjRxNEivO|IhcA>? NHXBO25qdmS3Y3XzJINmdGxiYYDvdJRwe2m| M2DkWVIzPzZ5MEKx
LS411N  NHi0Z41CeG:ydH;zbZMhSXO|YYm= M2jIclAvPSEQvF2= MUW3NkBp MlfObY5kemWjc3XzJGZieyCvUl7BJIxmfmWu NIO0bWozOjR4MU[5OS=>
MDA-MB-231 M3Pqc2Fxd3C2b4Ppd{BCe3OjeR?= NVTrVYFUOTBizszN MnPROFghcA>? M4XweJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVjLNpNjOjF6OEe2PVc>
MCF-7  Mo\QRZBweHSxc3nzJGF{e2G7 NWi3WW83OTBizszN MYW0PEBp MV7y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MWSyNVg5PzZ7Nx?=
A375 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDZNE42KM7:TR?= MUSxM|UwQCCm MYrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M1HqXlIyPzl4NkKy
SKMEL1 NWPJW5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3INE42KM7:TR?= NULMO41sOS93L{ig[C=> MYjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NH7LTpgzOTd7Nk[yNi=>
SKMEL3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCwMlUh|ryP NFjQTGgyNzVxODDk MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MX[yNVc6PjZ{Mh?=
SKMEL28 NGTpd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWiwMlUh|ryP M3XvbVEwPS96IHS= NFvlN|BqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MmXXNlE4QTZ4MkK=
MeWo MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTBNE42KM7:TR?= MWmxM|UwQCCm MoTKbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NXnnVZc6OjF5OU[2NlI>
B16 NEPxUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfESJkxNjVizszN NUDuU2RHOS93L{ig[C=> MYPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NYDM[GxROjF5OU[2NlI>
Ly 1 M3rzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6yOEBp MXjJR|UxRTdwMzFOwG0> NGGy[Y8zOTd5MkC0PS=>
Ly 7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPINlQhcA>? NEmzXpZKSzVyPUGwMlch|ryP NUXHXVlQOjF5N{KwOFk>
Su-DHL6 M{PMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu1NlQhcA>? NYnwSHBJUUN3MP-8olIxKM7:TR?= NX7SfnhLOjF5N{KwOFk>
Ly 10 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j2RlI1KGh? NUSwUG9mUUN3MP-8olIxKM7:TR?= MkjPNlE4PzJyNEm=
RIVA MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonwNlQhcA>? MWrJR|Ux97zgMkCg{txO MnnENlE4PzJyNEm=
Su-DHL2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnkNlQhcA>? NUTrTVJwUUN3MP-8olIxKM7:TR?= M1rIOVIyPzd{MES5
Ly 1 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW0PEBp M1fTdGlEPTB;MD6zOEDPxE1? M3ToeFIyPzd{MES5
Ly 7 MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O0W|Q5KGh? NIrCVVRKSzVyPUCuNFI2KM7:TR?= NUS1T4h[OjF5N{KwOFk>
Su-DHL6 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHCOFghcA>? NH6zTVhKSzVy78{eNlAh|ryP MlSyNlE4PzJyNEm=
Ly 10 M2Did2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[3RlQ5KGh? M1nUUWlEPTB;MT64JO69VQ>? NES3cHQzOTd5MkC0PS=>
RIVA M4\YNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHXVlFYPDhiaB?= MWHJR|Ux97zgMkCg{txO NYXuWVN4OjF5N{KwOFk>
Su-DHL2 NXu3T3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TsTFQ5KGh? M3jUVWlEPTB;MUeuOEDPxE1? M4PBc|IyPzd{MES5
Ly 1 NFzLXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHuV29[PzJiaB?= MYDJR|UxRTBwMEGg{txO Ml7sNlE4PzJyNEm=
Ly 7 M{LYPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp M2jWe2lEPTB;MD6wNVgh|ryP MXmyNVc4OjB2OR?=
Su-DHL6 NYL4OoNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXi3NkBp NXzCT|dLUUN3ME2xMlYh|ryP NYC5dpRXOjF5N{KwOFk>
Ly 10 NVLjb5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q2WlczKGh? MWXJR|UxRTFwMjFOwG0> NWe4UoFGOjF5N{KwOFk>
RIVA NFLvV3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXFPG9LPzJiaB?= MUPJR|Ux97zgMkCg{txO M1Lae|IyPzd{MES5
Su-DHL2 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTZW4t5PzJiaB?= MVLJR|UxRTFzLkKg{txO NHPZc2wzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID